Co-Diagnostics (NASDAQ: CODX) reported Q2 EPS of $0.33, $0.11 better than the analyst estimate of $0.22. Revenue for the quarter came in at $27.4 million versus the consensus estimate of $20.77 million.

GUIDANCE:

Co-Diagnostics sees Q3 2021 EPS of $0.19-$0.22, versus the consensus of $0.18. Co-Diagnostics sees Q3 2021 revenue of $23-25 million, versus the consensus of $18.12 million.

For earnings history and earnings-related data on Co-Diagnostics (CODX) click here.